-
A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice
- Back
Document Title
A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice
Author
Hunsawong T.,Sunintaboon P.,Warit S.,Thaisomboonsuk B.,Jarman R.G.,Yoon I.-K.,Ubol S.,Fernandez S.
Name from Authors Collection
Affiliations
Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand; Department of Virology, Armed Force Research Institute of Medical Sciences, Bangkok, Thailand; Department of Chemistry, Faculty of Science, Mahidol University, Bangkok, Thailand; Tuberculosis Research Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani, Thailand; Viral Diseases Branch, Walter Reed Army Institute of Research, Bethesda, MD, United States
Type
Article
Source Title
Vaccine
ISSN
0264410X
Year
2015
Volume
33
Issue
14
Open Access
All Open Access, Hybrid Gold
Publisher
Elsevier Ltd
DOI
10.1016/j.vaccine.2015.02.016
Abstract
Dengue virus (DENV), a member of the Flaviviridae family, can be transmitted to humans through the bite of infected Aedes mosquitoes. The incidence of dengue has increased worldwide over the past few decades. Inadequate vector control, changing global ecology, increased urbanization, and faster global travel are factors enhancing the rapid spread of the virus and its vector. In the absence of specific antiviral treatments, the search for a safe and effective vaccine grows more imperative. Many strategies have been utilized to develop dengue vaccines. Here, we demonstrate the immunogenic properties of a novel dengue nanovaccine (DNV), composed of ultraviolet radiation (UV)-inactivated DENV-2, which has been loaded into the nanoparticles containing chitosan/Mycobacterium bovis Bacillus Calmette-Guerin cell wall components (CS/BCG-NPs). We investigated the immunogenicity of DNV in a Swiss albino mouse model. Inoculation with various concentrations of vaccine (0.3, 1, 3 and 10μg/dose) with three doses, 15-day apart, induced strong anti-dengue IgM and IgG antibodies in the mouse serum along with neutralizing antibody against DENV-2 reference strain (16681), a clinical-isolate strain (00745/10) and the mouse-adapted New Guinea-C (NGC) strain. Cytokine and chemokine secretion in the serum of DNV-immunized mice showed elevated levels of IFN-γ, IL-2, IL-5, IL-12p40, IL-12p70, IL-17, eotaxin and RANTES, all of which have varying immune functions. Furthermore, we observed a DNV dose-dependent increase in the frequencies of IFN-γ-producing CD4+ and CD8+ T cells after in vitro stimulation of nucleated cells. Based on these findings, DNV has the potential to become a candidate dengue vaccine. © 2015.
Industrial Classification
Knowledge Taxonomy Level 1
Knowledge Taxonomy Level 2
Knowledge Taxonomy Level 3
License
CC BY-NC-ND
Rights
Elsevier B.V.
Publication Source
Scopus